Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cilo Cybin HoldingsJSE:CCC +66.67%2 Days Sales Outstanding is 138.29 as of Sep. 2025, which is 383% above its 10-year median of 28.62. GuruFocus rates JSE:CCC with a GF Score™ of 2/100. The stock has 5 warning signs investors should review. Among 947 Drug Manufacturers companies, Cilo Cybin Holdings ranks worse than 74.66% on this metric.
The historical rank and industry rank for Cilo Cybin Holdings's Days Sales Outstanding or its related term are showing as below:
JSE:CCC'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 28.62 Med: 28.62 Max: 103.32
Current: 103.32
During the past 3 years, Cilo Cybin Holdings's highest Days Sales Outstanding was 103.32. The lowest was 28.62. And the median was 28.62.
JSE:CCC's Days Sales Outstanding is ranked worse than 74.66% of 947
companies
in the Drug Manufacturers industry
Industry Median: 71.98
vs JSE:CCC: 103.32
Cilo Cybin Holdings's Days Sales Outstanding
increased
from Sep. 2024 () to Sep. 2025 (138.29).
Cilo Cybin Holdings (JSE:CCC) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Cilo Cybin Holdings Days Sales Outstanding Related Terms
Cilo Cybin Holdings Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Cilo Cybin Holdings's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cilo Cybin Holdings Days Sales Outstanding Chart
Cilo Cybin Holdings Annual Data
Trend
Mar23
Mar24
Mar25
Days Sales Outstanding
-
-
-
Cilo Cybin Holdings Semi-Annual Data
Sep24
Mar25
Sep25
Days Sales Outstanding
-
-
138.29
JSE:CCC vs ZTS, UTHR, VTRS: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cilo Cybin Holdings's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cilo Cybin Holdings Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cilo Cybin Holdings's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Cilo Cybin Holdings's Days Sales Outstanding falls into.
Cilo Cybin Holdings Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 138.29 mean?
Cilo Cybin Holdings (JSE:CCC) has a Days Sales Outstanding of 138.29 as of Sep. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Cilo Cybin Holdings and its competitors. This is 383% above median its historical median of 28.62. Over the past decade, Cilo Cybin Holdings' Days Sales Outstanding has ranged from 28.62 to 103.32. According to the industry distribution chart, Cilo Cybin Holdings ranks #707 out of 947 companies in the Drug Manufacturers industry, placing it in the top 74.7%.
Is Cilo Cybin Holdings' Days Sales Outstanding too high?
Cilo Cybin Holdings' current Days Sales Outstanding of 138.29 is 383% above median its 10-year median of 28.62. Over the past 10 years, this metric has ranged from a low of 28.62 to a high of 103.32. The Drug Manufacturers industry median Days Sales Outstanding is 71.98. Cilo Cybin Holdings' value of 138.29 is 92.1% above this industry median. Based on the distribution chart, Cilo Cybin Holdings ranks #707 out of 947 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cilo Cybin Holdings has a GF Score™ of 2/100, reflecting its overall financial health beyond just this single metric.
How does Cilo Cybin Holdings' Days Sales Outstanding compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cilo Cybin Holdings ranks #707 out of 947 companies for Days Sales Outstanding. This places Cilo Cybin Holdings in the lower half of its industry. The industry median Days Sales Outstanding is 71.98. Cilo Cybin Holdings' value of 138.29 is 92.1% above this benchmark. Historically, Cilo Cybin Holdings' own Days Sales Outstanding has ranged from 28.62 to 103.32 over the past decade. While the company's 10-year median is 28.62 vs. the industry median of 71.98, Cilo Cybin Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.98, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cilo Cybin Holdings's current Days Sales Outstanding of 138.29 is 92.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Cilo Cybin Holdings and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cilo Cybin Holdings's current Days Sales Outstanding is 138.29, which is 383% above median its own 10-year median of 28.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cilo Cybin Holdings stock overvalued right now?
Cilo Cybin Holdings (JSE:CCC) has a current Days Sales Outstanding of 138.29. The current Days Sales Outstanding is 138.29, which is 383% above median its 10-year median of 28.62 and 92.1% above the Drug Manufacturers industry median of 71.98. Cilo Cybin Holdings' overall GF Score™ is 2/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Cilo Cybin Holdings (JSE:CCC), the current Days Sales Outstanding is 138.29 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cilo Cybin Holdings Ltd is engaged in identifying viable investments in Biotech, Biohacking and Pharmaceutical businesses. It offers products and services in the medical cannabis sector.
2GF Score
Get the complete analysis for JSE:CCC
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:CCC has been successfully added to your 
